about
Phosphatidylinositol-5-phosphate activation and conserved substrate specificity of the myotubularin phosphatidylinositol 3-phosphatasesAlteration of energy substrates and ROS production in diabetic cardiomyopathySystemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptorsSitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoformsActivation of the endosome-associated ubiquitin isopeptidase AMSH by STAM, a component of the multivesicular body-sorting machinery.Diagnostic approaches for diabetic cardiomyopathy.Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.Proinflammatory actions of angiotensins.Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetesRole of the renin-angiotensin system in vascular diseases: expanding the field.Targeting metabolic disturbance in the diabetic heart.Inflammation and angiotensin II.Potential role of nuclear factor κB in diabetic cardiomyopathy.Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.Updating experimental models of diabetic cardiomyopathyN-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery DiseaseAngiotensin II increases connective tissue growth factor in the kidney.Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.The myotubularin family of lipid phosphatases.Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation.Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells.IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus.Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease.Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease.Differential redox regulation within the PTP superfamily.Analysis of phosphoinositide binding domain properties within the myotubularin-related protein MTMR3.Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables.Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis.Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and endosome related functions.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors.Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential.Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease.Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.
P50
Q24298042-455A58C0-F52A-4DE5-B3A4-F67D5344E76EQ27014882-7A5E43D5-A9BC-4F8A-9E93-69D830B97266Q28364369-D2BB0F5D-DA0A-4ACF-B925-B7E433C7AFE8Q28535415-36E1D609-F0A2-4BAA-AC9A-EC9F0CAD958DQ30159944-A97DF49E-C444-4762-A280-40A977A0C23BQ30362092-3C81E235-7992-4E21-A268-5BBE8B57A262Q33806760-9B32784F-267C-43C0-97E4-72A2A8B3A6FFQ34244757-DDD74E77-7E3B-49DD-AD33-E75BF3382C07Q34464759-8396ED97-D157-41CA-B66F-746C214F400BQ34467429-4AFE4940-7C10-4619-84A1-A09A91B6695EQ35084845-F94D3C69-AC2F-4649-906F-9875CF0F2BE0Q35099157-BF2E96CC-F38C-48B2-AAD3-0B976BD6A1A7Q35104570-49D6E90B-99E3-4DA8-BEDC-CD9A40846F05Q35153209-C876D1C9-6281-4976-91D0-9B59E0A7234FQ35564129-48B89B15-1F85-4D99-8AB7-72BCF130FEBCQ35689476-19B1222B-C2A2-4699-9A90-18D9DC0ACEEAQ35843514-F9A8215C-5656-4517-803B-957AE3800535Q36254177-727DFE9A-6178-4C43-9143-79FDADB70567Q36302905-E2C583FD-4F5D-4E5B-B299-CABC4056DD4CQ37473770-FB77F62D-7BC6-4104-8E32-74CC034DD56DQ37679639-C819B397-EE2C-4C3E-AABD-C783EF581699Q37736845-2449454A-8D24-4E0A-A2E2-AD43566F09A4Q39052557-5CAD6DF6-C3A0-4C25-94D9-886903B70DB8Q39403443-A7F2115E-3CEC-4536-88D3-D994F2F6599EQ40054806-5A7FEAEC-6079-462F-A384-274BB99D4477Q40084672-568A5CBF-317B-45D9-A809-54DF6E0AAB41Q40161680-3D5EDD37-F17A-4BE5-B0D2-8573BB7BC8AEQ40433158-380DED16-C766-4AB2-89C8-3D22A2BC7634Q41460824-53312213-8E42-4C92-98DC-49BA3BBB86DAQ41724254-9DF133C7-84CE-48C3-A6E8-5CB367E80A15Q44201217-F1BC4033-0405-458B-814A-43A2A0827EE2Q44571611-52333E02-67DE-41EF-9AC0-87F1E7809A1BQ44903329-9EAA202C-9009-4334-B13A-AC087F03DAE7Q46557284-5C3A26B9-DE2D-4F56-BA7A-C92F6FF4008EQ47037344-D334892E-645E-4256-A9EE-D9A4A6CF6511Q48043450-75B56214-A060-49C5-A9FF-235743DDB4B8Q48402889-F8AC667A-BF8C-485E-8FEF-B79B1DCABACAQ51615648-B1F6F72F-6523-49B6-8015-BEE1A0CB93EEQ51714847-EBA3416E-AD0F-4C36-B248-F61AAED27AEBQ53172065-A2B6BB18-6A98-4709-A4F0-315C75895CF3
P50
description
researcher ORCID ID = 0000-0001-5515-6078
@en
wetenschapper
@nl
name
Oscar Lorenzo
@ast
Oscar Lorenzo
@en
Oscar Lorenzo
@es
Oscar Lorenzo
@nl
type
label
Oscar Lorenzo
@ast
Oscar Lorenzo
@en
Oscar Lorenzo
@es
Oscar Lorenzo
@nl
prefLabel
Oscar Lorenzo
@ast
Oscar Lorenzo
@en
Oscar Lorenzo
@es
Oscar Lorenzo
@nl
P106
P31
P496
0000-0001-5515-6078